ClinicalTrials.gg
RecruitingNCT05509777AMAYUpdated Oct 7, 2026

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

A Phase 3 interventional study of Mirikizumab in Crohn's Disease, sponsored by Eli Lilly and Company. Recruiting at 81 sites in 16 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing mirikizumab in Crohn Disease — 7 open to participants now, 8 under way, 3 of them phase 3. mirikizumab · Crohn Disease.

Planned enrollment
7th of 10
90 · median 150
Started
2024
the only one that year
Phase 3
4 of 10
2 open now
Registered
5th of 10
by date
Lead sponsor
5 of 10
Eli Lilly and Company

Among the 10 studies testing mirikizumab in Crohn Disease, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 4 in phase 3, and was the 5th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

7 of the 10 studies testing mirikizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing mirikizumab in Crohn Disease, or all of them as a file.
02

Study summary

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease.

Study periods for the intervention-specific appendix (ISA) will be as follows:

  • A 12-week induction period
  • A maintenance period from Week 12 to Week 52, and
  • A safety follow-up period up to 16 weeks.

The study will last about 74 weeks and may include up to 19 visits.

Read the detailed description

Participants screened in the MACARONI-23 Platform study could be randomized to mirikizumab to participate in this intervention specific arm of the study.

03

Conditions studied

  • Crohn's Disease

Keywords

  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a diagnosis of CD or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
  • Participants have moderately to severely active CD (as defined by a baseline PCDAI score ≥30).
  • Participants must have endoscopy with evidence of active CD defined as SES-CD score ≥6 (or ≥4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0.
  • Participants must have a documented history of inadequate response, loss of response or intolerance to at least one medication used to treat CD, which may include immunomodulators, oral or IV , a biologic therapy or a JAK inhibitor.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestations that might be anticipated to require surgery.
  • Participants must not have an abscess.
  • Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Mirikizumab Dose 1

    Mirikizumab administered intravenously (IV) or subcutaneously (SC) in participants that weigh greater than (\>) 40 kilograms (kg).

    Drug: Mirikizumab

  • Experimental
    Mirikizumab Dose 2

    Mirikizumab administered IV or SC in participants that weigh \>20 kg to less than or equal to (≤) 40 kg. Dosing is based on assessments of the participant's weight and appropriate weight class.

    Drug: Mirikizumab

  • Experimental
    Mirikizumab Dose 3

    Mirikizumab administered IV or SC in participants that weigh greater than or equal to (≥) 9 kg to less than or equal to ≤20 kg. Dosing is based on assessments of the participant's weight and appropriate weight class.

    Drug: Mirikizumab

Interventions

  • Administered IV or SC

    Also known as: LY3074828

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Clinical Response by Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12 and Endoscopic Response by Simple Endoscopic Score for CD (SES-CD) at Week 52

    Clinical response based on PCDAI, and endoscopic response based on SES-CD.

    Time frame: Baseline to Week 52

  2. Percentage of Participants with a Clinical Response by PCDAI at Week 12 and Clinical Remission by PCDAI at Week 52

    Clinical response based on PCDAI, and clinical remission based on PCDAI.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Percentage of Participants Achieving Clinical Response by PCDAI

    Clinical response based on PCDAI.

    Time frame: Week 12

  2. Percentage of Participants Achieving Clinical Response by Clinical Disease Activity Index (CDAI)

    Clinical response based on CDAI for participants ≥12 years of age

    Time frame: Week 12

  3. Percentage of Participants Achieving Clinical Remission by PCDAI

    Clinical remission based on PCDAI.

    Time frame: Week 12

  4. Percentage of Participants Achieving Clinical Remission by CDAI

    Clinical remission based on CDAI for participants ≥12 years of age.

    Time frame: Week 12

  5. Percentage of Participants Who Achieve PCDAI Clinical Response at Week 12 and PCDAI Clinical Remission and Endoscopic Remission at Week 52

    Time frame: Baseline to Week 52

  6. Percentage of Participants Who Achieve PCDAI Clinical Remission and Endoscopic Remission at Week 52

    Time frame: Week 52

  7. Percentage of Participants Achieving Clinical Response by PCDAI at Week 12 and Endoscopic Remission by SES-CD at Week 52

    Time frame: Baseline to Week 52

  8. Change from Baseline in C-reactive Protein (CRP)

    Time frame: Baseline, Week 12

  9. Change from Baseline in CRP

    Time frame: Baseline, Week 52

  10. Change from Baseline in Fecal calprotectin

    Time frame: Baseline, Week 12

  11. Change from Baseline in Fecal calprotectin

    Time frame: Baseline, Week 52

  12. Percentage of Participants Achieving Clinical Response PCDAI at Week 12 and Clinical Remission by CDAI at Week 52

    Clinical response by PCDAI, CDAI for participants ≥12 years of age

    Time frame: Baseline to Week 52

  13. Percentage of Participants Achieving Endoscopic Response

    Time frame: Week 52

  14. Percentage of Participants Achieving Clinical Remission by PCDAI

    Clinical remission based on PCDAI

    Time frame: Week 52

  15. Percentage of Participants Achieving Clinical Response by PCDAI at Week 12 and PCDAI Clinical Remission without the use of Corticosteroids and Who Did Not Have Crohn's Disease (CD)-Related Surgery at Week 52

    Clinical response and clinical remission by PCDAI

    Time frame: Baseline to Week 52

  16. Pharmacokinetics (PK): Clearance of Mirikizumab

    Time frame: Baseline through Week 52

  17. Pharmacokinetics (PK): Volume of Distribution of Mirikizumab

    Time frame: Baseline through Week 52

07

Study locations

71 of 81 sites recruiting
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
    Not yet recruiting
    • · Contact310-248-8516
    • David Ziring · Principal investigator
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06032, United States
    Recruiting
    • · Contact860-837-5591
    • Jeffrey Hyams · Principal investigator
  • Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
    • · Contact404-727-4542
    • subra kugathasan · Principal investigator
  • Children's Center for Digestive Health Care, LLC
    Atlanta, Georgia 30342, United States
    Recruiting
    • Jeffery Lewis · Principal investigator
  • Riley Childrens Hospital
    Indianapolis, Indiana 46202, United States
    Recruiting
    • · Contact317-274-5858
    • Steven Steiner · Principal investigator
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
    Not yet recruiting
    • · Contact617-355-6058
    • Athos Bousvaros · Principal investigator
  • Atlantic Children's Health--Pediatric Gastroenterology
    Morristown, New Jersey 07960, United States
    Not yet recruiting
    • · Contact973-971-6489
    • Oren Koslowe · Principal investigator
  • Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC)
    New York, New York 10021-5663, United States
    Recruiting
    • · Contact646-962-7162
    • Aliza Solomon · Principal investigator
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • · Contact212-659-9443
    • David Dunkin · Principal investigator
  • Columbia University Medical Center/New York Presbyterian
    New York, New York 10032, United States
    Recruiting
    • Joseph Picoraro · Principal investigator
  • Childrens Medical Center
    Dayton, Ohio 45404, United States
    Recruiting
    • · Contact937-641-5605
    • Shehzad Saeed · Principal investigator
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19146, United States
    Recruiting
    • · Contact973-971-7747
    • Arthur Kastl · Principal investigator
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
    Recruiting
    • Clifton Huang · Principal investigator
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
    Recruiting
    • · Contact802-656-9402
    • Jillian Sullivan · Principal investigator
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
    Not yet recruiting
    • · Contact206-987-1293
    • Ghassan Wahbeh · Principal investigator
  • AKH - Medizinische Universtität Wien
    Vienna, 1090, Austria
    Recruiting
    • Judith Pichler · Principal investigator
  • Universitair Ziekenhuis Brussel
    Brussels, 1090, Belgium
    Recruiting
    • · Contact3224774795
    • Elisabeth De Greef · Principal investigator
  • Cliniques universitaires Saint-Luc
    Brussels, 1200, Belgium
    Recruiting
    • · Contact+32 2 764 19 33
    • Francoise Smets · Principal investigator
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
    Recruiting
    • · Contact3293321338
    • Pauline De Bruyne · Principal investigator
  • UZ Leuven
    Leuven, 3000, Belgium
    Recruiting
    • Ilse Hoffman · Principal investigator
  • Hospital PUC-CAMPINAS
    Campinas, 13060-904, Brazil
    Recruiting
    • · Contact+55 19 3343-8465
    • Joaquim Simoes Neto · Principal investigator
  • Hospital Pequeno Príncipe
    Curitiba-PR, 80250-060, Brazil
    Recruiting
    • · Contact+55 (41) 2108-3861
    • Sabine Krüger Truppel · Principal investigator
  • Hospital das Clínicas - UFG (Universidade Federal de Goiás)
    Goiânia, 74605-050, Brazil
    Recruiting
    • · Contact55(62) 98607-3907
    • Naflesia Oliveira Correa · Principal investigator
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, 90035-903, Brazil
    Recruiting
    • · Contact+55 51 3359-6331
    • Luciana Harlacher · Principal investigator
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre
    Porto Alegre, 90050-170, Brazil
    Recruiting
    • · Contact+55 51 3214-8143
    • Cristina Ferreira · Principal investigator
  • NDI - Nucleo de Doenças Infecciosas
    Santos Dumont, 29040-091, Brazil
    Recruiting
    • · Contact+55 (27) 999036155
    • Ana Daniela Izoton de Sadovsky · Principal investigator
  • Integral Pesquisa e Ensino
    Votuporanga, 15501 405, Brazil
    Recruiting
    • Herlon Valerio · Principal investigator
  • IWK Health Centre
    Halifax, B3K 6R8, Canada
    Recruiting
    • · Contact1-902-470-7009
    • Anthony Otley · Principal investigator
  • London Health Sciences Centre (LHSC) - Victoria Hospital
    London, N6A 5W9, Canada
    Recruiting
    • · Contact519-685-8500 x56074
    • Dhandapani Ashok · Principal investigator
  • The Hospital for Sick Children
    Toronto, M5G 1X8, Canada
    Recruiting
    • Thomas Walters · Principal investigator
  • Children's & Women's Health Centre of British Columbia
    Vancouver, V6H 3V4, Canada
    Not yet recruiting
    • Kevan Jacobson · Principal investigator
  • URC CIC
    Paris, 75015, France
    Terminated

    Not enrolling at this site — choose another above.

  • Soroka Medical Center
    Beersheba, 8410101, Israel
    Recruiting
    • Baruch Yerushalmi · Principal investigator
  • Shamir Medical Center (Assaf Harofeh)
    Israel, 70300, Israel
    Recruiting
    • EFRAT BROIDE · Principal investigator
  • Shaare Zedek
    Jerusalem, 9103102, Israel
    Recruiting
    • Dan Turner · Principal investigator
  • Hadassah University Hospital, Ein Kerem,
    Jerusalem, 9112001, Israel
    Recruiting
    • · Contact+972528709824
    • Zev Davidovics · Principal investigator
  • Schneider Children's Medical Center
    Petah Tikva, 4920235, Israel
    Recruiting
    • · Contact+972-39253039
    • Dror Shouval · Principal investigator
  • Kaplan Medical Center, Pediatric Gastroenterology Dept.
    Rehovot, 7661041, Israel
    Not yet recruiting
    • · Contact972526274987
    • Amit Assa · Principal investigator
  • Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e C. Arrigo
    Alessandria, 15121, Italy
    Not yet recruiting
    • · Contact+39 0131206893
    • Felici Enrico · Principal investigator
  • Asst Papa Giovanni Xxiii Bergamo
    Bergamo, 24127, Italy
    Recruiting
    • · Contact"39 0352673448 39 0352674553"
    • Naire Sansotta · Principal investigator
  • Azienda USL di Bologna
    Bologna, 40133, Italy
    Recruiting
    • · Contact39 3313198290
    • Patrizia Alvisi · Principal investigator
  • SOC Gastroenterologia e Nutrizione - AOU Meyer (Primo Piano Ala OVEST, accettazione DH centralizzato)
    Florence, 50139, Italy
    Recruiting
    • · Contact39 055-566295039
    • Paolo Lionetti · Principal investigator
  • Ospedale dei Bambini Vittore Buzzi
    Milan, 20154, Italy
    Recruiting
    • · Contact393400968832
    • Lorenzo Norsa · Principal investigator
  • Gastroenterologia ed epatologia pediatrica (Piano terra della Clinica Pediatrica)
    Roma, CAP 00161, Italy
    Recruiting
    • · Contact393404111671
    • Salvatore Oliva · Principal investigator
  • Juntendo University Hospital
    Bunkyō City, 113-8431, Japan
    Recruiting
    • · Contact81120023812
    • Takahiro Kudo · Principal investigator
  • Hirosaki University Hospital
    Hirosaki, 036, Japan
    Recruiting
    • · Contact81120023812
    • Hirotake Sakuraba · Principal investigator
  • Kagoshima University Hospital
    Kagoshima, 890-8520, Japan
    Recruiting
    • · Contact81120023812
    • Takuro Nishikawa · Principal investigator
  • Kokikai Tsujinaka Hospital Kashiwanoha
    Kashiwa-shi, 277-0871, Japan
    Recruiting
    • · Contact81120023812
    • Ken Takeuchi · Principal investigator
  • Kobe University Hospital
    Kobe, 650-0017, Japan
    Recruiting
    • · Contact81120023812
    • Tomoko Horinouchi · Principal investigator
  • Saga University Hospital
    Saga, 849-8501, Japan
    Recruiting
    • · Contact81120023812
    • Toshihiko Kakiuchi · Principal investigator
  • Miyagi Children's Hospital
    Sendai, 989 3126, Japan
    Recruiting
    • · Contact81120023812
    • Daiki Abukawa · Principal investigator
  • National Center for Child Health and Development
    Setagaya-ku, 157-8535, Japan
    Recruiting
    • · Contact81120023812
    • Katsuhiro Arai · Principal investigator
  • Mie University Hospital
    Tsu, 514-8507, Japan
    Not yet recruiting
    • · Contact81120023812
    • Yuki Koike · Principal investigator
  • Yamaguchi University Hospital
    Ube, 755-8505, Japan
    Recruiting
    • · Contact81120023812
    • Azuma Yoshihiro · Principal investigator
  • Saiseikai Yokohamashi Tobu Hospital
    Yokohama, 2308765, Japan
    Not yet recruiting
    • · Contact81120023812
    • Shuichiro Umetsu · Principal investigator
  • Yokohama City University Medical Center, Center of IBD
    Yokohama, 232-0024, Japan
    Recruiting
    • · Contact81120023812
    • Reiko Kunisaki · Principal investigator
  • Erasmus Medisch Centrum
    Rotterdam, 3015 CN, Netherlands
    Recruiting
    • · Contact+31 (0)10 70 36111
    • J.C. Escher · Principal investigator
  • Akershus Universitetssykehus
    Nordbyagen, 01474, Norway
    Recruiting
    • · Contact+47 67960335
    • Christopher Inchley · Principal investigator
  • Oslo University Hospital
    Oslo, 0450, Norway
    Recruiting
    • · Contact+4722117611/ +4790108309
    • Gori Perminow · Principal investigator
  • Universitetssykehuset Nord-Norge
    Tromsø, 9038, Norway
    Recruiting
    • Lene Trulsen · Principal investigator
  • St-Olavs Hospital
    Trondheim, 7030, Norway
    Recruiting
    • · Contact4773553497
    • Henrik Dollner · Principal investigator
  • Korczowski Bartosz, Gabinet Lekarski
    Rzeszów, 35-302, Poland
    Recruiting
    • Bartosz Korczowski · Principal investigator
  • Warsaw IBD Point Profesor Kierkus
    Warsaw, 00-728, Poland
    Recruiting
    • · Contact+48517191061
    • Monika Meglicka · Principal investigator
  • Instytut Pomnik-Centrum Zdrowia Dziecka
    Warsaw, 04-730, Poland
    Recruiting
    • · Contact+48 668 171 443
    • Jaroslaw Kierkus · Principal investigator
  • Centro Clínico Académico - Braga (2CA-Braga) (Hospital de Braga)
    Braga, 4710-243, Portugal
    Recruiting
    • Filipa Neiva · Principal investigator
  • Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
    Lisbon, 1649-035, Portugal
    Recruiting
    • Ana Isabel Lopes · Principal investigator
  • Centro Hospitalar de São João, E.P.E.
    Porto, 4200 319, Portugal
    Recruiting
    • Eunice Trindade · Principal investigator
  • Inje University Haeundae Paik Hospital
    Busan, 48108, South Korea
    Recruiting
    • Tae-oh Kim · Principal investigator
  • Kyungpook National University Chilgok Hospital
    Daegu, 41404, South Korea
    Recruiting
    • Ben Kang · Principal investigator
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
    Recruiting
    • Hong Koh · Principal investigator
  • Samsung Medical Center
    Seoul, 06351, South Korea
    Recruiting
    • · Contact82234100641
    • Yon Ho Choe · Principal investigator
  • Seoul National University Hospital
    Seoul, 3080, South Korea
    Recruiting
    • · ContactContact Number: 821092233320
    • Jin Soo Moon · Principal investigator
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
    Recruiting
    • · Contact+ 393465970480
    • Rafael Gonzlez de Caldas · Principal investigator
  • Corporacio Sanitaria Parc Tauli
    Sabadell, 08208, Spain
    Recruiting
    • Diana Garcia Tirado · Principal investigator
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
    Recruiting
    • Marisa Isabel Colomino · Principal investigator
  • Royal Hospital for Children and Young People
    Edinburgh, EH16 4TJ, United Kingdom
    Recruiting
    • Richard Russell · Principal investigator
  • Oxford University Hospitals NHS trust John Radcliffe hospital
    Headington, OX3 9DU, United Kingdom
    Recruiting
    • · Contact01865 231592
    • Lucy Howarth · Principal investigator
  • Great Ormond Street Hospital For Children NHS Foundation Trust
    London, WC1N 3JH, United Kingdom
    Recruiting
    • Kelsey Jones · Principal investigator
  • Manchester University NHS Foundation Trust
    Manchester, M139WL, United Kingdom
    Recruiting
    • · Contact+0161 701 6948
    • Andrew Fagbemi · Principal investigator
  • Sheffield Children's Hospital
    Sheffield, S10 2RX, United Kingdom
    Recruiting
    • · Contact0114 2267980
    • Akshay Kapoor · Principal investigator
  • Royal London Hospital
    Whitechapel, E1 1FR, United Kingdom
    Recruiting
    • Ahmed Kadir · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's planned 45 months is close to that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2022
First posted
Aug 22, 2022
StartActual
Mar 13, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Apr 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • SOC Gastroenterologia e Nutrizione - AOU Meyer (Primo Piano Ala OVEST, accettazione DH centralizzato) · Florence, ItalyContact •••2950→•••5039
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • SOC Gastroenterologia e Nutrizione - AOU Meyer (Primo Piano Ala OVEST, accettazione DH centralizzato) · Florence, ItalyContact •••2950→•••5039
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05509777
Responsible party
Sponsor
First posted
Aug 22, 2022
Start date
Mar 13, 2024
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion